GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

Prior Therapy

1st Line

IRB# 20744
Pembrolizumab + Lenvatinib + TACE (Transarterial Chemoembolization) vs Placebo + TACE in Intermediate Stage HCC

2nd Line or more

IRB# 20929
Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARUMAB) for the treatment of advanced hepatocellular carcinoma

Cholangiocarcinoma

1st Line

IRB# 20357
[NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

2nd Line

IRB# 16033
Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Fluorouracil and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma

1st or 2nd Line

No Trials Currently Available

2nd Line or more

No Trials Currently Available

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131 (MATCH)

KEY
- Open to Enrollment
- In Development
- Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
IRB# 23005
EA2197, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial